Clinical Scorecard: The Involvement of Homeobox Genes in Positive Feedback Mechanisms of Signaling Pathways and Their Implications for Cancer Treatment
At a Glance
Category
Detail
Condition
Cancer
Key Mechanisms
Positive-feedback loops between pathway receptor components and downstream transcription factors, particularly homeobox genes.
Target Population
Patients with cancer, particularly those undergoing epithelial–mesenchymal transition (EMT).
Care Setting
Oncology
Key Highlights
Interaction between receptor components of signaling pathways and homeobox genes.
Positive-feedback loops are central to tumor plasticity and development.
Focus on RTK–RAS-related signaling pathways and their implications for cancer.
Potential use of RTK- or RAS-targeted inhibitors with epigenetic drugs.
Emphasis on blocking both input and transcriptional output of activated pathways.
Guideline-Based Recommendations
Diagnosis
Management
Consider RTK- or RAS-targeted inhibitors in combination with epigenetic drugs.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with cancer exhibiting EMT.
Combination therapies targeting signaling pathways and transcriptional outputs.
Clinical Best Practices
Explore the role of homeobox genes in cancer therapy.
Investigate positive-feedback mechanisms in signaling pathways.
